Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

11.83 -0.99 (-7.75%)
Streaming Delayed Price Updated: 1:58 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
A Look at MiNK Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For March 18, 2025 ↗
 
Via Benzinga
News headline image
Examining the Future: MiNK Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Tuesday's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
From MiNK Therapeutics
Via GlobeNewswire
News headline image
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024 ↗
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
MiNK Reports Second Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
From MiNK Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.